- Home
- ATGE vs AXSM Comparison
ATGE vs AXSM Comparison
Compare ATGE & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATGE
- AXSM
- Stock Information
- Founded
- ATGE 1987
- AXSM 2012
- Country
- ATGE United States
- AXSM United States
- Employees
- ATGE N/A
- AXSM N/A
- Industry
- ATGE Other Consumer Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- ATGE Consumer Discretionary
- AXSM Health Care
- Exchange
- ATGE Nasdaq
- AXSM Nasdaq
- Market Cap
- ATGE 5.5B
- AXSM 5.9B
- IPO Year
- ATGE 1991
- AXSM 2015
- Fundamental
- Price
- ATGE $144.06
- AXSM $119.31
- Analyst Decision
- ATGE Strong Buy
- AXSM Strong Buy
- Analyst Count
- ATGE 3
- AXSM 19
- Target Price
- ATGE $139.00
- AXSM $174.26
- AVG Volume (30 Days)
- ATGE 372.0K
- AXSM 498.1K
- Earning Date
- ATGE 10-30-2025
- AXSM 11-11-2025
- Dividend Yield
- ATGE N/A
- AXSM N/A
- EPS Growth
- ATGE 82.07
- AXSM N/A
- EPS
- ATGE 6.18
- AXSM N/A
- Revenue
- ATGE $1,788,290,000.00
- AXSM $495,033,000.00
- Revenue This Year
- ATGE $9.77
- AXSM $63.62
- Revenue Next Year
- ATGE $6.32
- AXSM $55.72
- P/E Ratio
- ATGE $24.21
- AXSM N/A
- Revenue Growth
- ATGE 12.85
- AXSM 69.83
- 52 Week Low
- ATGE $71.09
- AXSM $75.56
- 52 Week High
- ATGE $155.39
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- ATGE 54.44
- AXSM 54.25
- Support Level
- ATGE $147.85
- AXSM $117.60
- Resistance Level
- ATGE $151.36
- AXSM $122.14
- Average True Range (ATR)
- ATGE 3.99
- AXSM 3.15
- MACD
- ATGE -0.53
- AXSM -0.22
- Stochastic Oscillator
- ATGE 40.35
- AXSM 47.09
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.